AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing ... Read More
Danaher wraps up $5.7bn acquisition of Abcam to bolster life sciences segment
Danaher Corporation (NYSE: DHR), a renowned global science and technology innovator, has announced the completion of its acquisition of Abcam plc (NASDAQ: ABCM), a key ... Read More
Danaher to acquire protein consumables supplier Abcam for $5.7bn
Danaher Corporation (NYSE: DHR), a global science and technology innovator, has announced a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier ... Read More
Boston mass shooting sends shockwaves, seven hospitalized amid Caribbean festival
In a horrifying turn of events that has shattered the city's festive spirit, at least seven people have been rushed to the hospital following a ... Read More
Microbiome company Vedanta Biosciences raises $68m in Series D
Vedanta Biosciences, a clinical-stage microbiome company founded by PureTech Health, has raised $68 million in a Series D financing round led by affiliates of Magnetar ... Read More
Nipocalimab developer Momenta Pharmaceuticals to be acquired by J&J
J&J acquisition of Momenta Pharmaceuticals : US healthcare giant Johnson & Johnson (J&J) has signed a $6.5 billion deal to acquire Momenta Pharmaceuticals, a biotech ... Read More
Precision oncology company Black Diamond Therapeutics raises $85m
Black Diamond Therapeutics, a precision oncology company based in Cambridge, has raised $85 million from a Series C financing round led by Boxer Capital of ... Read More
Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of ... Read More
X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two ... Read More
Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases
In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical giant Novartis to create Anthos Therapeutics, a ... Read More